Psonet

Drugs in development

New therapies in development for psoriasis: what changes in clinical research?

Biological drugs have been considered a scientific and clinical progress in the treatment of psoriasis. However, their role can be fully assessed only when randomized controlled trials will compare them with each other and with conventional drugs, and when data efficacy and safety in the long term will become available  

Meanwhile, search for new molecules carries on and in the near future new therapies will become available: some of these drugs are already used in clinical Phase II and III, while others are in early stages of development.

For drugs close to market, it seems desirable to rely on post-marketing evaluation systems: studies of efficacy and long-term safety, comparison and for assessing outcomes (end point) clinically relevant outcomes, not surrogates.

Here you can find an overview of the state of the art of these new molecules. Information on clinical trials in progress will be regularly updated.

Mechanism Compound Administration route Phase Sponsor

 JAK inhibitor

ABT-494

Upadacitinib
Oral

III

AbbVie

CF101

piclidenoson

Oral

III

Can-Fite BioPharma
For Itch Serlopitant Oral III

Menlo Therapeutics Inc.

 

IL-23 inhibitor Mirikizumab Subcutaneous

III

 

Eli Lilly and Company
  MC201 Topical

II

Drug Delivery Solutions Ltd.
Biosimilar BI 695501 Subcutaneous

III

Boehringer Ingelheim

IL-17 inhibitor

BCD085

 

Subcutenaous

III

Biocad

ROCK2 inibitor KD025 Oral

II

Kadmon Corporation, LLC
IL-17A, IL-17F inhibitor M1095 nanobody Subcutaneous

IIb

Bond Avillion 2 Development LP
Phytotherapy TC cream Topical

II

Psoriasis Research Institute of Guangzhou

Supplement Psorax35 Oral

 

Arctic Nutrition AS
Anthracene derivative Anthralin By etosome ance liposome

 

Assiut University
  Enstilar® aereosol foam
Topical

 

LEO Pharma
RORg agonist
AZD0284 Oral

I

AstraZeneca
Hormone ACTHar Topical

I

IRIS Research and Development, LLC
Tyk2 inhibitor
BMS-986165

 Oral

 III

Bristol-Myers Squibb
Monoclonal antibody Bimekizumab  

III

UCB Biopharma S.P.R.L.
  Ultrasound     University of Cagliari
  Fecal microbiota transplantation By gastroscopy   Odense University Hospital
IL-23 inhibitor

SCH900222

tildrakizumab

Subcutaneous III Merck Sharp & Dohme Corp.

IL-23 inhibitor

 

BI 655066/ABBV-066

(Risankizumab)

Subcutaneous III AbbVie
  SPA therapy   III Association Francaise pour la Recherche Thermale
JAK inhibitor PF-06700841 topical IIb Pfizer
         
         
  L      
         

Read more

You can find more information about ongoing clinical trials and drugs in development at the following addresses:

http://www.clinicaltrials.gov/

https://www.psoriasis.org/drug-pipeline

http://controlled-trials.com/ 

http://www.who.int/ictrp/en/

http://www.anzctr.org.au/default.aspx